LIGAND PHARMACEUTICALS INC — Director's Dealing 2018

Jul 4, 2018

SEC Form 4/A — Form 4/A

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2018-06-19

Reporting Person: Aryeh Jason (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-19	Non-Qualified Stock Option (right to buy)	$195.91	A	2474	Acquired	2028-06-18	Common Stock (2474)	Direct

Footnotes

F1: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date.

F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.